Back

CKD Evaluation and Management

PLEASE NOTE

While the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD remains the current global standard, a focused update to “Chapter 3: Delaying CKD progression and managing its complications” is currently underway to address emerging evidence on SGLT2 inhibitors, GLP-1-based therapies, and nonsteroidal mineralocorticoid receptor antagonists in people with CKD without diabetes.

The KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease was published in March 2024 in Kidney International. Co-chaired by Adeera Levin, MD (Canada) and Paul Stevens, MB (United Kingdom), this update to the 2012 guideline provides actionable, evidence-based recommendations for healthcare professionals, patients, caregivers, and policymakers worldwide. Key topics include CKD classification and risk assessment, management of complications, medication stewardship, and patient-centered care across diverse clinical settings.

Treatment approaches and actionable guideline recommendations are based on a systematic review of relevant studies and appraisal of the certainty of the evidence and the strength of recommendations, following the “Grading of Recommendations Assessment, Development, and Evaluation” (GRADE) approach. The guideline provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and includes useful infographics. The guideline also introduces a dedicated research agenda to advance the evidence base in CKD.